{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:33:56Z","timestamp":1780090436609,"version":"3.54.0"},"reference-count":84,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T00:00:00Z","timestamp":1311811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:p>A number of drug classes are licensed for the treatment of osteoporosis including bisphosphonates, recombinant human parathyroid hormone (PTH), strontium, hormone replacement therapy (HRT), selective oestrogen receptor modulators (SERMS) and denosumab. This review discusses the safety of osteoporosis treatments and their efficacies. Recent concerns about the safety of calcium and high-dose vitamin D are discussed. Bisphosphonates have substantial postmarketing experience and a clearer picture of safety issues is emerging. Along with the well recognized effects on the gastrointestinal tract and kidney function, recently described adverse effects such as osteonecrosis of the jaw, oesophageal cancer, atrial fibrillation, subtrochanteric femur fractures and ocular complications of bisphosphonate therapy are discussed. Therapy with PTH is limited to two years\u2019 duration because of the development of osteogenic sarcomas in animal studies, which appeared related to dose, duration and timing of therapy. Strontium should be used with caution in patients with renal impairment and its use has been associated with venous thromboembolism. The role of HRT and SERMs in the treatment of postmenopausal osteoporosis is restricted as a result of an increased risk of stroke, venous thromboembolism and breast cancer. Postmarketing experience with denusomab is limited but a number of potential safety concerns including osteonecrosis of the jaw are emerging. All of these drugs have been proven to reduce fractures. The decision to use a drug to reduce fracture risk should be based on risk\u2013benefit analysis of the drug and its suitability for individual patients.<\/jats:p>","DOI":"10.1177\/2042098611411012","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T08:03:45Z","timestamp":1311840225000},"page":"159-172","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["Safety of drugs used in the treatment of osteoporosis"],"prefix":"10.1177","volume":"2","author":[{"given":"Cora","family":"McGreevy","sequence":"first","affiliation":[{"name":"Department of Medicine for the Elderly, RCSI and Beaumont Hospital, Dublin 9, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Medicine for the Elderly, RCSI and Beaumont Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,7,28]]},"reference":[{"key":"bibr1-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081247"},{"key":"bibr2-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1159\/000223695"},{"key":"bibr3-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.14.1701"},{"key":"bibr4-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/s00596-008-0035-4"},{"key":"bibr5-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-0030-9"},{"key":"bibr6-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.600"},{"key":"bibr7-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"bibr8-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067312"},{"key":"bibr9-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1126\/science.2528207"},{"key":"bibr10-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3691"},{"key":"bibr11-2042098611411012","first-page":"U2339","volume":"118","author":"Bolland M.J.","year":"2006","journal-title":"N Z Med J"},{"key":"bibr12-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.193"},{"key":"bibr13-2042098611411012","doi-asserted-by":"publisher","DOI":"10.3111\/200104051062"},{"key":"bibr14-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1098"},{"key":"bibr15-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.13.1729"},{"key":"bibr16-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-006-9008-y"},{"key":"bibr17-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040325"},{"key":"bibr18-2042098611411012","unstructured":"CHMP (2009) Assessment report on bisphosphonates and osteonecrosis of the jaw. Available at: http:\/\/www.emea.europa.eu (accessed 8 May 2011)."},{"key":"bibr19-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3856"},{"key":"bibr20-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1210\/er.2001-3002"},{"key":"bibr21-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.24.2077"},{"issue":"1","key":"bibr22-2042098611411012","first-page":"S81","volume":"23","author":"Cummings S.R.","year":"2008","journal-title":"J Bone Miner Res"},{"key":"bibr23-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"bibr24-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.12.004"},{"key":"bibr25-2042098611411012","doi-asserted-by":"crossref","unstructured":"Dawson-Hughes, B. (2010) Reply to\n                      \u2018Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis\u2019. BMJ\n                      341: c3691. Available at: http:\/\/www.bmj.com\/content\/341\/bmj.c3691\/reply\n                      (accessed 8 May 2011)\n                      .","DOI":"10.1136\/bmj.c3691"},{"key":"bibr26-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1285-3"},{"key":"bibr27-2042098611411012","doi-asserted-by":"publisher","DOI":"10.2165\/11206440-000000000-00000"},{"key":"bibr28-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8750"},{"key":"bibr29-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1602-9"},{"key":"bibr30-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5463"},{"key":"bibr31-2042098611411012","unstructured":"EMEA (2004) 2004-Protelos. The Committee for Medicinal Products for Human Use."},{"key":"bibr32-2042098611411012","unstructured":"EMEA (2007) 2007-Protelos. Press release. Available at: http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/protelos\/PressRelease_Protelos_ 41745807en.pdf (accessed 8 May 2011)."},{"key":"bibr33-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.7.1217"},{"key":"bibr34-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"bibr35-2042098611411012","unstructured":"FDA (2008) FDA update 2008. Available at: http:\/\/www.fda.gov.\/cder\/drug\/early_comm\/bisphosphonates_update_200811.htm (accessed 8 May 2011)."},{"key":"bibr36-2042098611411012","unstructured":"FDA (2009) Denosumab meeting briefing document, 13 August. FDA Update Advisory Committee for Reproductive Health Drugs. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM176623.pdf (accessed 15 December 2010)."},{"key":"bibr37-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200303203481225"},{"key":"bibr38-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(02)01840-8"},{"key":"bibr39-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4444"},{"key":"bibr40-2042098611411012","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-5-200703060-00005"},{"key":"bibr41-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1132"},{"key":"bibr42-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070112"},{"key":"bibr43-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.06.009"},{"key":"bibr44-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.10.004"},{"key":"bibr45-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.4.721"},{"key":"bibr46-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1006\/bulm.1999.0146"},{"key":"bibr47-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0707493"},{"key":"bibr48-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074941"},{"key":"bibr49-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72902-2"},{"key":"bibr50-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00071.x"},{"key":"bibr51-2042098611411012","unstructured":"MHRA (2009) MHRA drug safety update, March 2009. Medicines and Healthcare Products Regulatory Agency. Available at: http:\/\/www.mhra.gov.uk\/Publications\/Safetyguidance\/DrugSafetyUpdate\/CON041211."},{"key":"bibr52-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050817"},{"key":"bibr53-2042098611411012","unstructured":"National Institute for Health and Clinical Excellence (2008) Alendronate, etidronate, risedronate, raloxifene, strontium and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, October. Available at: www.nice.org.uk (accessed 8 May 2011)."},{"key":"bibr54-2042098611411012","volume-title":"Clinician's Guide to Prevention and Treatment of Osteoporosis","author":"National Osteoporosis Foundation (NOF)","year":"2010"},{"key":"bibr55-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.7.872"},{"issue":"3","key":"bibr56-2042098611411012","first-page":"CD005326","author":"O'Donnell S.","year":"2006","journal-title":"Cochr Database Syst Rev"},{"key":"bibr57-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0952"},{"key":"bibr58-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.356"},{"key":"bibr59-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-008-0734-8"},{"key":"bibr60-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7435.335"},{"key":"bibr61-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/PL00004171"},{"key":"bibr62-2042098611411012","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.2009.28097"},{"key":"bibr63-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011807"},{"key":"bibr64-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040920"},{"key":"bibr65-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"bibr66-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-009-0294-0"},{"key":"bibr67-2042098611411012","doi-asserted-by":"crossref","unstructured":"Sanders, K.M., Stuart, A.L., Williamson, E.J., Simpson, J.A., Kotowicz, M.A., Young, D.\n                      et al\n                      . (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.\n                      JAMA\n                      303: 1815\u20131822.","DOI":"10.1001\/jama.2010.594"},{"key":"bibr68-2042098611411012","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090506"},{"key":"bibr69-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.12.006"},{"key":"bibr70-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra053077"},{"key":"bibr71-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.253"},{"key":"bibr72-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080710"},{"key":"bibr73-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61342-7"},{"key":"bibr74-2042098611411012","volume":"15","author":"Taylor K.H.","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"bibr75-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7387.469"},{"key":"bibr76-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1947"},{"key":"bibr77-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011203032102"},{"key":"bibr78-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1210\/er.2001-5002"},{"key":"bibr79-2042098611411012","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00009"},{"key":"bibr80-2042098611411012","unstructured":"World Health Organization (2006) Fracture risk assessment tool. Available at http:\/\/www.shef.ac.uk\/FRAX\/ (accessed 25 August 2010)."},{"key":"bibr81-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0808738"},{"key":"bibr82-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4506"},{"key":"bibr83-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.7.3597"},{"key":"bibr84-2042098611411012","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1346.019"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098611411012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2042098611411012","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2042098611411012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:37:29Z","timestamp":1777592249000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2042098611411012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,28]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1177\/2042098611411012"],"URL":"https:\/\/doi.org\/10.1177\/2042098611411012","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,28]]}}}